AmbioDry™ Ultrastructural Characteristics Abstracted at the Annual ARVO Research Meeting

COSTA MESA, California – 8 May 2003 – At the annual meeting of the Association of Research in Vision and Ophthalmology, the unique ultrastructural features of AmbioDry Amniotic Membrane Allografts were detailed in a poster presentation by Dr. Thomas John (Loyola University, Maywood IL, Cornea Research Center).

Various, standard histological methods were employed for analysis including light microscopy, scanning electron microscopy and transmission electron microscopy. The research detailed mean hydration thickness, collagen structure and cellular distribution.

The introduction of this new AmbioDry™ dehydrated HAM adds another dimension to amniotic membrane surgery. The absence of a carrier sheet allows direct ocular application of this new HAM. AmbioDry™ dehydrated HAM without intact epithelial cells and easy handling characteristics make it a good choice for HAM transplantation.

AmbioDry Allografts, dehydrated tissue grafts derived from human placenta, are employed by eye surgeons for the treatment of a variety of ocular surface disorders and defects. AmbioDry Allografts are processed in the United States in alliance with Celgene Corporation.

In comparison to competitive tissue options, the advantages of the AmbioDry are vast: decellularized, sterile tissue matrix; shelf-life storage; prepares in minutes for surgery; substrate-free; consistent tissue quality.

“Dr. Thomas John is the leader in histological examination of amniotic membrane technologies for eye surgery. His research data details the differentiating features of the AmbioDry and further confirms the advantages and benefits of the technology”, stated Erich Ziegler, President of OKTO Ophtho.

About OKTO

Founded in 2000, OKTO Ophtho develops and commercializes specialized, leading-edge surgical technologies for eye surgery. OKTO’s purpose is to develop surgical solutions that improve the quality of life for patients, elevate the performance and productivity of eye care professionals, and lower costs to the provider.

OKTO currently holds leadership positions with surgical devices for oculoplastic surgeries and bio-implant technologies for ocular surface/ophthalmic reconstructive

Media Contact:

pr@oktoophtho.com